Salarius Pharmaceuticals Inc Stock Price, News & Analysis

Salarius Pharmaceuticals presented promising data from its ongoing Phase 1/2 clinical trials for its drug candidate, seclidemstat, targeting Ewing sarcoma and Advanced Solid Tumors (AST) during the ASCO Annual Meeting.

Initial drug activity was observed in patients with relapsed/refractory Ewing sarcoma and FET-rearranged sarcomas, indicating stable disease and prolonged time to progression. Seclidemstat demonstrated a manageable safety profile, with no significant hematological toxicities, and showcased potential efficacy, leading to further exploration in clinical settings.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced preliminary drug activity for its candidate, seclidemstat, observed in relapsed/refractory Ewing sarcoma and advanced solid tumors. The company shared three abstracts at the ASCO 2021 Annual Meeting, revealing a manageable safety profile and proof-of-concept activity. Key findings highlighted a recommended phase 2 dose of 900 mg BID, with patients experiencing significant tumor shrinkage. The abstracts cover ongoing trials and safety data supporting further investigation of seclidemstat.

Salarius Pharmaceuticals (Nasdaq: SLRX) reported a net loss of $1.9 million or $0.06 per share for Q1 2021, an improvement from a loss of $2.1 million or $0.22 per share in Q1 2020. Cash and cash equivalents totaled $36.6 million, supporting the clinical trials of lead drug candidate, seclidemstat, in Ewing sarcoma and FET-rearranged sarcomas. The company has initiated the dose-expansion stage of its Phase 1/2 trial, with preliminary efficacy signals emerging. A conference call is scheduled for May 12, 2021, to discuss these results further.

Salarius Pharmaceuticals (Nasdaq: SLRX) will host a conference call and live audio webcast on May 12, 2021, at 5:00 p.m. ET to discuss its Q1 2021 financial results. The company focuses on developing new medicines for pediatric cancers and solid tumors, with its lead candidate, seclidemstat, currently in a Phase 1/2 trial for relapsed Ewing sarcoma. Salarius has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA for its Ewing sarcoma program. An audio archive of the call will be available for 90 days post-event.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that all three of its abstracts detailing research on seclidemstat have been accepted for poster presentations at the 2021 ASCO Annual Meeting, scheduled for June 4-8, 2021. One of the abstracts will also be featured in a poster discussion session. The findings address clinical trials focusing on potential treatments for pediatric cancers and advanced solid tumors. Seclidemstat has received multiple designations from the FDA, including Fast Track and Orphan Drug Designation.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that three research abstracts on seclidemstat have been accepted for presentations at the 2021 ASCO Annual Meeting from June 4-8, 2021. One of these abstracts will be featured in a poster discussion session. The findings from the ongoing Phase 1/2 trial of seclidemstat in relapsed Ewing sarcoma will be detailed at the conference. Seclidemstat is being developed as a treatment for pediatric and other cancers with significant unmet needs, and has received multiple designations from the FDA.

Salarius Pharmaceuticals (Nasdaq: SLRX) reported its year-end results for 2020, highlighting significant progress in developing its LSD1 inhibitor, seclidemstat, for treating Ewing sarcoma and other cancers. The company completed the dose-escalation stage of its Phase 1/2 trial and established a recommended Phase 2 dose. Financially, Salarius is well-capitalized with approximately $37 million in cash from recent offerings. The net loss per share significantly decreased to $0.10 in Q4 2020 from $0.46 in Q4 2019, while the full-year loss was $0.50 compared to $2.12 in 2019.

Salarius Pharmaceuticals (SLRX) will host a conference call on March 18, 2021, at 4:30 p.m. ET to discuss its Q4 2020 and full year 2020 financial results. The company, focused on developing treatments for pediatric cancers, has its lead candidate, seclidemstat, in a Phase 1/2 trial for Ewing sarcoma, having received several designations from the FDA aimed at expediting its development. The call details include U.S. and international dial-in numbers, with a webcast available on the company’s investor site.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced the closing of its public offering of 16,806,722 shares at $1.3685 per share, generating approximately $23 million in gross proceeds. This financing boosts Salarius' cash availability to around $37 million, sufficient to support ongoing clinical trials for its lead drug candidate, seclidemstat. The funding aims to enhance treatment for Ewing sarcoma and other cancers. Delivery of clinical trial data is anticipated in June 2021, presenting potential regulatory pathways and commercial opportunities.